Dr. Baley is not exclusive to any brand or technology. Every patient's case determines the right implant — not the other way around. A transparent look at the full spectrum available.
The full Polytech catalog is available at this practice. So is Motiva, Mentor, and Eurosilicon. The implant choice is a clinical decision made case by case — based on your anatomy, your goals, your tissue characteristics, and the latest available safety data. No brand agreement, no inventory pressure, no agenda.
What follows is an honest overview of the technologies Dr. Baley uses most — their certifications, the clinical evidence, and why each has a place in specific cases.
A three-dimensional polyurethane foam surface that allows tissue to grow into the implant matrix — anchoring it, reducing rotation, and lowering capsular contracture rates. CE-certified under EU MDR. Used in rePlantation® for specific clinical indications.
Polytech's Microthane® implants are coated with a three-dimensional open-pore polyurethane foam matrix. Unlike standard smooth or macro-textured surfaces, this coating allows tissue to grow directly into the implant — anchoring it in place, virtually eliminating rotation, and dramatically reducing capsular contracture rates.
Polytech has operated a patient registry since 2007 — one of the longest-running post-market surveillance programs in the industry. The Mesmo 5-year study, published 2022, followed 919 patients: zero cases of BIA-ALCL.
In 2019, France banned all macro-textured and polyurethane implants. The scientific community's response was divided. The European Association of Aesthetic Plastic Surgeons (EUSOMA/ESSO) published a position paper questioning whether the ban was clinically justified or over-cautious — noting that polyurethane implants have a distinct biological mechanism from macro-textured surfaces and should not be grouped together.
The Netherlands' RIVM — asked by its own government to assess the scientific basis of France's decision — concluded that the evidence did not justify a ban beyond Allergan's Biocell product specifically. Polytech publicly contested the ANSM ruling as not based on scientific proof. The US FDA, the UK MHRA, and most European regulators did not follow France's lead.
Australia's TGA suspended some Polytech products as part of a broader precautionary review. This position has since been revisited in the global literature. Most of Europe, Latin America, and Asia continue to offer Polytech PU under CE certification.
The polyurethane foam creates a microenvironment at the implant-tissue interface. Tissue grows into the open-pore matrix, effectively anchoring the implant in a way that smooth and even textured shells cannot replicate. This is why rotation rates are nearly zero, and why capsular contracture — the most common long-term complication of breast implant surgery — is markedly reduced.
The surface is biocompatible and has been used in cardiovascular and other medical applications for decades before its use in breast implants.
B-Lite is a genuinely novel material — the first meaningful innovation in breast implant composition in a generation. Hollow microspheres developed for the aerospace industry, permanently bonded within cohesive silicone gel.
Standard silicone implants exert gravitational force on breast tissue — every day, for years. This cumulative mechanical stress contributes to ptosis (sagging), tissue thinning, and long-term shape change. B-Lite directly addresses this by reducing the weight of the implant by approximately 30% while maintaining equivalent volume, profile, and feel.
The hollow microspheres used in B-Lite gel are made from borosilicate glass — the same material used in medical and aerospace applications. They are permanently encapsulated within the silicone matrix and biocompatible by independent testing.
A 5-year post-market study found 94.9% of patients rated aesthetic outcome as satisfied or very satisfied. 95.5% rated natural look and feel as satisfied or very satisfied. No new or unexpected safety signals. The study confirmed that reduced mechanical load on tissue translates to measurable improvements in long-term breast shape stability.
For patients who specifically want an FDA-approved implant, or whose anatomy calls for a different approach, the following options are all available. The full consultation determines which is right.
The first new breast implant to receive FDA Premarket Approval since 2013 — approved in 2024, making Motiva the most recently FDA-approved breast implant in the US market. Zero cases of BIA-ALCL in over 3 million implants distributed globally since 2010. Available in 85+ countries. CE-marked since 2011. SmoothSilk® surface and Ergonomix® ergonomic shape range — implants that respond to body position the way natural tissue does.
One of the two longest-established FDA-approved implant brands in the United States. MemoryGel® cohesive silicone gel and MemoryShape® anatomical range. Decades of post-market safety data. A conservative, well-documented choice for patients who prioritize the FDA track record above all else. Smooth and moderately textured surface options available.
A CE-certified European manufacturer offering smooth and micro-textured silicone gel implants. A strong option for patients who want a well-tested implant without the premium of larger brands. Round and anatomical profiles available. Solid clinical track record across European and Latin American markets. Available in all relevant anatomical sizes and projections.
Dr. Baley reviews your anatomy, your history, and your goals — then recommends the implant that fits. No sales agenda. No predetermined answer. Just the right clinical choice for you.
